Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1

The clinical heterogeneity of prostate cancer (PCa) makes it difficult to identify those patients that could benefit from more aggressive treatments. As a contribution to a better understanding of the genomic changes in the primary tumor that are associated with the development of high-risk disease,...

Descripción completa

Detalles Bibliográficos
Autores principales: Spans, Lien, Van den Broeck, Thomas, Smeets, Elien, Prekovic, Stefan, Thienpont, Bernard, Lambrechts, Diether, Karnes, R. Jeffrey, Erho, Nicholas, Alshalalfa, Mohammed, Davicioni, Elai, Helsen, Christine, Gevaert, Thomas, Tosco, Lorenzo, Haustermans, Karin, Lerut, Evelyne, Joniau, Steven, Claessens, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029704/
https://www.ncbi.nlm.nih.gov/pubmed/27014907
http://dx.doi.org/10.18632/oncotarget.8220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029704/
https://www.ncbi.nlm.nih.gov/pubmed/27014907
http://dx.doi.org/10.18632/oncotarget.8220

Ejemplares similares